Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions

Vaccine

Volumn 31, Issue 1, 2012, Pages 109-113

  Powell, Suzanne E ^a   Hariri, Susan ^a   Steinau, Martin ^b   Bauer, Heidi M ^c   Bennett, Nancy M ^d   Bloch, Karen C ^e   Niccolai, Linda M ^f   Schafer, Sean ^g   Unger, Elizabeth R ^b   Markowitz, Lauri E ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f YALE UNIVERSITY   (United States)

^g OREGON HEALTH AUTHORITY   (United States)

Author keywords

Cervical intraepithelial neoplasia (CIN; Human papillomavirus (HPV); Vaccine impact

Indexed keywords

DNA;

ADULT; ARTICLE; CONTROLLED STUDY; DNA FINGERPRINTING; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PUBLIC HEALTH INSURANCE; SCREENING; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL DISEASES; YOUNG ADULT;

EID: 84870487671     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.10.092     Document Type: Article

References (21)

1. Centers for Disease Control National vaccination coverage among adolescents aged 13-17 years - United States, 2006. MMWR Morb Mortal Wkly Rep 2007, 56(August (34)):885-888.
2. Centers for Disease Control FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010, 59(May (20)):626-629.
3. Hildesheim A., Herrero R., Wacholder S., Rodriguez A.C., Solomon D., Bratti M.C., et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007, 298(August (7)):743-753.
4. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356(May (19)):1928-1943.
5. Group FIS Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356(May (19)):1915-1927.
6. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., Unger E.R., et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007, 56(March (RR-2)):1-24.
7. Markowitz L.E., Hariri S., Unger E.R., Saraiya M., Datta S.D., Dunne E.F. Post-licensure monitoring of HPV vaccine in the United States. Vaccine 2010, 28(July (30)):4731-4737.
8. Brotherton J.M., Fridman M., May C.L., Chappell G., Saville A.M., Gertg D.M. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011, 377(June (9783)):2085-2092.
9. Saraiya M., Hariri S. HPV vaccine effect: is the glass half full or half empty?. Lancet 2011, 377(June (9783)):2057-2058.
10. Centers for Disease Control Progress in immunization information systems - United States, 2010. MMWR Morb Mortal Wkly Rep 2012, 61(June):464-467.
11. Broome C.V., Facklam R.R., Fraser D.W. Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med 1980, 303(September (10)):549-552.
12. Andrews N., Waight P.A., Borrow R., Ladhani S., George R.C., Slack M.P., et al. Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and Wales. PLoS ONE 2011, 6(December (12)):e28435.
13. Hariri S., Unger E.R., Powell S.E., Bauer H.M., Bennett N.M., Bloch K.C., et al. The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions. Cancer Causes Control 2012, 23(February (2)):281-288.
14. Gargano J.W., Wilkinson E.J., Unger E.R., Steinau M., Watson M., Huang Y., et al. Prevalence of human papillomavirus types in invasive vulvar cancers and vulvar intraepithelial neoplasia 3 in the United States before vaccine introduction. J Low Genit Tract Dis 2012, 16(October (4)):471-479.
15. Steinau M., Patel S.S., Unger E.R. Efficient DNA extraction for HPV genotyping in formalin-fixed, paraffin-embedded tissues. J Mol Diagn 2011, 13(July (4)):377-381.
16. Hariri S., Steinau M., Rinas A., Gargano J.W., Ludema C., Unger E.R., et al. HPV genotypes in high grade cervical lesions and invasive cervical carcinoma as detected by two commercial DNA assays, North Carolina, 2001-2006. PLoS ONE 2012, 7(3):e34044.
17. Rand C.M., Schaffer S.J., Humiston S.G., Albertin C.S., Shone L.P., Heintz E.V., et al. Patient-provider communication and human papillomavirus vaccine acceptance. Clin Pediatr 2011, 50(February (2)):106-113.
18. Niccolai L.M., Mehta N.R., Hadler J.L. Racial/ethnic and poverty disparities in human papillomavirus vaccination completion. Am J Prev Med 2011, 41(October (4)):428-433.
19. Olsson S.E., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 2009, 5(October (10)):696-704.
20. Castle P.E., Rodriguez A.C., Burk R.D., Herrero R., Wacholder S., Alfaro M., et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ 2009, 339:b2569.
21. Mehta N.R., Julian P.J., Meek J.I., Sosa L.E., Bilinski A., Hariri S., et al. Human papillomavirus vaccination history among women with precancerous cervical lesions: disparities and barriers. Obstet Gynecol 2012, 119(March (3)):575-581.